CRISPR Therapeutics AG vs Mesoblast Limited: SG&A Expense Trends

SG&A Expense Trends: CRISPR Therapeutics AG vs Mesoblast Limited

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of two prominent biotech companies: CRISPR Therapeutics AG and Mesoblast Limited, from 2014 to 2023.

CRISPR Therapeutics AG has shown a remarkable upward trend in SG&A expenses, peaking in 2021 with a 1,900% increase from 2014. This surge reflects the company's aggressive expansion and investment in research and development. However, 2023 saw a 26% decline, indicating a potential shift in strategy or cost optimization.

Conversely, Mesoblast Limited's SG&A expenses have been relatively stable, with a slight decrease of 2% from 2014 to 2023. This stability suggests a consistent operational approach, despite the challenges in the biotech sector.

These trends offer valuable insights into the strategic priorities and financial health of these companies, guiding investment decisions in the ever-evolving biotech landscape.